CUTANEOUS T-CELL LYMPHOMA

This early-stage trial is testing the safety of a new gene therapy for adults with certain T-cell lymphomas that have returned or not responded to prior treatments. Doctors will collect a patient's own immune cells, genetically modify them in a lab to target a protein (CCR4) foun…

This study is testing if a drug called ruxolitinib can help patients with T-cell lymphoma stay in remission after a stem cell transplant. The drug is taken daily for a year to try to prevent the cancer from coming back and to reduce a dangerous complication where the donor cells …

This study is testing whether a light-based blood treatment called photopheresis can help control early-stage cutaneous T-cell lymphoma (CTCL), a type of skin cancer. Researchers want to see if using this treatment earlier in the disease course, rather than just for late stages, …

This study is testing an oral medication called golidocitnib for people with slow-growing T/NK-cell lymphomas that have come back or haven't responded to prior treatments. The goal is to see if this once-daily pill can effectively shrink tumors and control the disease. Researcher…

This early-stage study aims to find out if it's safe to combine two treatments for a type of skin lymphoma called mycosis fungoides. Researchers will give participants the drug bexarotene along with a special, low-dose radiation treatment that covers the entire skin surface. They…

This study is testing whether a gel called HyBryte, which is activated by a special light, can help treat early-stage cutaneous T-cell lymphoma (CTCL), a type of skin cancer. About 80 participants will apply the gel or a placebo to their skin patches twice a week for 18 weeks, fo…

This study is testing whether a topical cream containing tofacitinib can safely and effectively treat early-stage cutaneous T-cell lymphoma, a rare type of skin cancer. The trial will enroll 20 adults whose cancer has returned or hasn't responded to at least one previous standard…

This is an early-stage study testing a new intravenous drug called ST-001 for people with T-cell lymphoma that has come back or not responded to prior treatments. The main goals are to find the highest safe dose and understand how the drug works in the body. It is for adults whos…

This study is testing whether combining two existing cancer drugs (pembrolizumab and mogamulizumab) can help control advanced cutaneous T-cell lymphoma that has returned or stopped responding to previous treatments. The trial will enroll about 23 adults with this rare type of ski…

This early-stage study is testing a medication called ropeginterferon for people with advanced cutaneous T-cell lymphoma (CTCL), a type of skin cancer. The main goals are to find the safest and most effective dose and to see how well the drug works in patients whose disease hasn'…

This study aims to understand how doctors treat a rare type of skin cancer called cutaneous T-cell lymphoma in real-world practice. Researchers will look back at the medical records of 400 patients who received treatments between 2016 and 2023. The goal is to see which treatments…

This study aims to collect blood, urine, and skin samples from adults with specific skin conditions like cutaneous T-cell lymphoma, eczema, or atopic dermatitis. The purpose is to build a collection of samples for researchers to study. By analyzing these samples, scientists hope …